Gabriella Malacari
Physician Assistant · Dover, DENPI 1003307737
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 157 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 11.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,093 and has fallen 55.3% since, to $488 in 2025. Among physician assistant clinicians in DE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 157 payments — averaging $17.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceuticals, Inc.$307
- Lilly USA, LLC$294
- AbbVie$264
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$255
- Novo Nordisk$197
- Biohaven Pharmaceutical Holding Company Ltd.$104
- plus $1K from 28 others
What the payments were for
- Food & beverage$2,756100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biohaven Pharmaceuticals, Inc. | 24 | $307 |
| Lilly USA, LLC | 18 | $294 |
| AbbVie | 14 | $264 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $255 |
| Novo Nordisk | 13 | $197 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $104 |
| Astellas Pharma US Inc | 6 | $103 |
| Merck | 6 | $99 |
| Ardelyx, Inc. | 4 | $94 |
| QOL Medical, LLC | 2 | $86 |
| Ipsen Biopharmaceuticals, Inc | 3 | $79 |
| Phathom Pharmaceuticals, Inc. | 5 | $78 |
| Johnson & Johnson | 3 | $75 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $72 |
| AstraZeneca | 4 | $58 |
| GSK | 4 | $58 |
| Dexcom, Inc. | 3 | $54 |
| Pfizer | 3 | $46 |
| Bristol Myers Squibb | 3 | $44 |
| Abbott | 3 | $43 |
| Fresenius Kabi USA, LLC | 2 | $34 |
| Amgen | 1 | $32 |
| Digestive Care, Inc. | 1 | $31 |
| Novartis | 2 | $31 |
| Boehringer Ingelheim | 2 | $31 |
| Tactile Systems Technology Inc | 1 | $29 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| Aimmune Therapeutics, Inc. | 1 | $25 |
| Bayer | 1 | $25 |
| Intercept Pharmaceuticals, Inc. | 1 | $23 |
| Avanir Pharmaceuticals, Inc. | 1 | $19 |
| Braintree Laboratories, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $15 |
| Genentech USA, Inc. | 2 | $6 |
How this compares
$2,756 in reported general payments places this provider in the 90th percentile of 527 physician assistant providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 11 | $76,775 |
| CreonLipase/Protease/Amylase | 20 | $10,712 |
| Omeprazole | 151 | $2,206 |
| Esomeprazole Magnesium | 16 | $836 |
| Pantoprazole Sodium | 25 | $448 |
| Famotidine | 20 | $385 |
| Dicyclomine Hcl | 14 | $241 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon | $264 | $10,71220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 527 physician assistant providers in Delaware.
Other physician assistant in Dover
- James LustDover$30K
- Dana FioriDover$5K
- Anastazia AcevedoDover$5K
- Xzyla DownesDover$5K
- Ronnie DiemDover$4K
- Allison RabeDover$3K
- Todd BrandtDover$2K
- Dennis HoranDover$2K
- Jenny XiaoDover$2K
- Jennifer RahnLewes$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.